GlassScriptPhysician profile
Davender S Khera
NPI 1225165657
$7,866.60
in general payments reported to CMS, 2019-2025
53 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,518 · 2020: $906 · 2021: $437 · 2022: $744 · 2023: $1,528 · 2024: $1,606 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,261.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,349.18 | 2021-2025 | |
| Ge Healthcare | $669.89 | 2019-2025 | |
| Eisai INC. | $469.40 | 2022-2025 | |
| Ucb, INC. | $405.03 | 2019-2025 | Fintepla, Rystiggo, Zilbrysq |
| Amgen INC. | $365.92 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $363.45 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Acorda Therapeutics, INC | $329.06 | 2019-2024 | Inbrija |
| Neurocrine Biosciences, INC. | $302.47 | 2019-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $287.64 | 2019-2025 | Ultomiris |
| Pfizer INC. | $248.01 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $186.45 | 2019-2024 | Rytary, Crexont, Ongentys |
| Lilly USA, LLC | $183.46 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Novartis Pharmaceuticals Corporation | $176.55 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $151.24 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $145.09 | 2019-2023 | Nuplazid |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davender Khera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.